CGGBP1 Inhibitors
Chemical inhibitors of CGGBP1 can exert their inhibitory effects through various biochemical pathways. Geldanamycin, for instance, targets Hsp90, a molecular chaperone essential for the correct folding and functioning of many proteins. As such, geldanamycin can indirectly lead to the destabilization of CGGBP1 by preventing its proper folding and stabilization, which is critical for its DNA-binding activity. Similarly, Withaferin A inhibits annexin II, which is involved in the organization of the cytoskeleton. Since CGGBP1 may rely on interactions with cytoskeletal elements for its cellular functions, the disruption of annexin II by Withaferin A can impair CGGBP1's role in the cell.
In addition, Trichostatin A, an inhibitor of histone deacetylases, can alter the acetylation state of histones and potentially other proteins, including CGGBP1. Altered acetylation can affect the DNA-binding capability of CGGBP1 by changing its conformation or interaction with DNA. Alsterpaullone, a cyclin-dependent kinase inhibitor, can prevent the phosphorylation of CGGBP1, assuming that its activity is regulated by such post-translational modifications. This inhibition of phosphorylation could translate into functional inhibition of CGGBP1. U0126 and PD98059, both inhibitors of MEK, could inhibit the MAPK/ERK signaling pathway, which may be crucial for the activation of CGGBP1. LY294002 and Wortmannin, inhibitors of PI3K, could prevent the activation of CGGBP1 by interfering with PI3K signaling pathways. Rapamycin's inhibition of mTOR signaling could also impede any mTOR-dependent regulation of CGGBP1. SB203580 and SP600125, specific inhibitors of p38 MAP kinase and JNK, respectively, can affect the signaling pathways that could modulate CGGBP1 activity. Finally, Y-27632, a ROCK inhibitor, might affect CGGBP1's function related to actin cytoskeleton dynamics by inhibiting the Rho-ROCK signaling pathway.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Geldanamycin binds to Hsp90, a chaperone protein that is critical for the stability and function of various client proteins. Inhibition of Hsp90 by Geldanamycin could lead to the destabilization of CGGBP1, as it may rely on Hsp90 for proper folding and function. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A is known to bind to annexin II and inhibit its function. As annexin II is involved in cytoskeleton organization, its inhibition could disrupt cellular networks that CGGBP1 may interact with, leading to a functional inhibition of CGGBP1. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDACs). As HDACs can regulate the acetylation state of proteins and thus their function, Trichostatin A could alter the acetylation state of CGGBP1, potentially inhibiting its DNA binding capability. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor. If CGGBP1 function is regulated by phosphorylation through CDKs, Alsterpaullone could inhibit this modification and thus inhibit CGGBP1 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. If CGGBP1 requires PI3K signaling for full functionality, inhibition of PI3K by LY294002 would inhibit CGGBP1 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is a key regulator of cell growth and proliferation. If CGGBP1 function is influenced by mTOR signaling, Rapamycin would inhibit this pathway and potentially inhibit CGGBP1 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. Inhibition of this pathway by PD98059 could result in the functional inhibition of CGGBP1 if it is regulated by this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. If CGGBP1 function is modulated by p38 MAPK signaling, inhibition by SB203580 could reduce CGGBP1's functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK. If the activity of CGGBP1 is modulated by JNK signaling, inhibition by SP600125 could lead to a decrease in CGGBP1 functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an irreversible inhibitor of PI3K. If CGGBP1 function depends on PI3K signaling, inhibition by Wortmannin could lead to functional inhibition of CGGBP1. | ||||||